This website is intended for healthcare professionals who are currently residing and practising in the United Kingdom and Ireland.
This is a promotional website designed, built and funded by Gilead Sciences Ltd.
UK-AMB-1047 | January 2024 © 2024 Gilead Sciences, Inc. All rights reserved
Intensive Care Society State of the Art meeting 2022: The hidden threat of IFIs in the ICU
AmBisome® (liposomal amphotericin B): a successful example of nanotechnology applied to pharma
The evolving role of viral infection on the development of invasive fungal disease: Novel immunomodulators and the role of fungal diagnostics
Intensive Care Society State of the Art meeting 2022: The hidden threat of IFIs in the ICU
Watch Gilead’s symposium from the Intensive Care Society State of the Art Meeting 2022 held in Belfast. Dr Eavan Muldoon presents on how to diagnose IFIs in the ICU.
Prescribing information can be found at the top or bottom of this webpage
UK-AMB-0677
Date of preparation: January 2023.
Intensive Care Society State of the Art meeting 2022: The hidden threat of IFIs in the ICU
ViewAmBisome® (liposomal amphotericin B): a successful example of nanotechnology applied to pharma
ViewThe evolving role of viral infection on the development of invasive fungal disease: Novel immunomodulators and the role of fungal diagnostics
ViewIntensive Care Society State of the Art meeting 2022: The hidden threat of IFIs in the ICU
ViewThis link will take you to a non-Gilead website. Gilead does not recommend, endorse or accept liability for sites controlled by third parties.